Relypsa (RLYP) Could Be Next High-Profile Takeout, Says Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform
November 9, 2015 9:36 AM ESTLeerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings report. Results came in relatively in line with consensus on both the top and bottom lines, with total revenue of $5.95B vs. $5.97B consensus. EPS was reported at $1.03 vs. $1.02.
Analyst Seamus Fernandez commented, "We are updating our AZN model post 3Q results, which came in... More
AstraZeneca/ZSHP Acquisition Highlights Relypsa (RLYP) is Undervalued - Oppenheimer
November 9, 2015 9:33 AM ESTOppenheimer analyst, Ling Wang, believes Relypsa (NASDAQ: RLYP) is undervalued after the acquisition of ZSPH at a value of $2.7B. Competitor ZS-9's interim 52-week data were presented from phase III ZS-005 trial and Wang believes the drugs presented by each company have comparable... More
Relypsa (RLYP) Poised to Open Higher Following AstraZeneca (AZN)/ZS Pharma (ZSPH) Deal
November 6, 2015 6:53 AM ESTRelypsa (NASDAQ: RLYP) shares are poised higher after AstraZeneca (NYSE: AZN) agreed to acquire ZS Pharma (NASDAQ: ZSPH) for $2.7 billion. Shares of Relypsa are set to open higher by 20%.
... More